Show Summary Details
Page of

Oral BG-12 for Relapsing-Remitting Multiple Sclerosis, Part II: The CONFIRM Trial 

Oral BG-12 for Relapsing-Remitting Multiple Sclerosis, Part II: The CONFIRM Trial
Chapter:
Oral BG-12 for Relapsing-Remitting Multiple Sclerosis, Part II: The CONFIRM Trial
Author(s):

Mary A. Bailey

DOI:
10.1093/med/9780199377527.003.0017
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 21 September 2019

This chapter provides a summary of a landmark study in multiple sclerosis. Is oral BG-12 safe and efficacious for treating relapsing-remitting multiple sclerosis (RRMS) compared to glatiramer acetate? Starting with that question, it describes the basics of the study, including funding, study location, who was studied, how many patients, study design, study intervention, follow-up, endpoints, results, and criticism and limitations. In patients with RRMS, oral BG-12 has been shown to be an effective disease-modifying therapy versus glatiramer or placebo. This gives physicians and patients more options for MS treatments than the well-known, established injectable therapies. The chapter briefly reviews other relevant studies and information, and concludes with a relevant clinical case.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.